APVO News and Press, Aptevo Therapeutics Inc. From 12/21/18

Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced...

SEATTLE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30 th Annual Piper Jaffray Healthcare Conference on Tuesda...

Gainers:  Daxor (NYSEMKT: DXR ) +86% . Electro Scientific Industries (NASDAQ: ESIO ) +88% . Heidrick & Struggles International (NASDAQ: HSII ) +33% . Pioneer Energy Services (NYSE: PES ) +31% . Veracyte (NASDAQ: VCYT ) +29% . Under Armour (NYSE: UAA ) +26% . Chegg (NYSE: CHG...

Unfortunately, small and micro-cap stocks sometimes correct on no news in a risk-off environment, even when they have everything going for them. Such is the case for the recent correction of Aptevo Therapeutics ( APVO ). The stock is a gem in the micro-cap biotech space, because it's one o...